MPR Weekly Dose Podcast #271 — Foundayo Now Available, Meets Safety Endpoints; Filspari, Sdamlo Approved; FDA Encourages TRT Makers to Purse Label Expansion

Foundayo, an oral GLP-1, now available for weight loss; results from the ACHIEVE-4 trial; Filspari gains approval for FSGS; a new formulation of amlodipine, and the FDA signals support for broader use of testosterone replacement therapy.

Episode metadata supplied by the publisher feed · Published Apr 17, 2026

Embed this episode

Attribution link and audio player

Ready to play

MPR Weekly Dose Podcast #271 — Foundayo Now Available, Meets Safety Endpoints; Filspari, Sdamlo Approved; FDA Encourages TRT Makers to Purse Label Expansion

0:00 14:45

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of MPR Weekly Dose?

This episode is 14 minutes long.

When was this MPR Weekly Dose episode published?

This episode was published on April 17, 2026.

Can I download this MPR Weekly Dose episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!